Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; gleevec) therapyATALLAH, Ehab; TALPAZ, Moshe; O'BRIEN, Susan et al.Cancer. 2002, Vol 94, Num 11, pp 2996-2999, issn 0008-543XArticle

A phase 2 study of imatinib in patients with relapsed or refractory philadelphia chromosome-positive acute lymphoid leukemiasOTTMANN, Oliver G; DRUKER, Brian J; BACCARANI, Michele et al.Blood. 2002, Vol 100, Num 6, pp 1965-1971, issn 0006-4971, 7 p.Article

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyTALPAZ, Moshe; SILVER, Richard T; HOCHHAUS, Andreas et al.Blood. 2002, Vol 99, Num 6, pp 1928-1937, issn 0006-4971Article

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosomeDRUKER, Brian J; SAWYERS, Charles L; KANTARJIAN, Hagop et al.The New England journal of medicine. 2001, Vol 344, Num 14, pp 1038-1042, issn 0028-4793Article